BRISBANE, Calif., March 2 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today that Dan Welch, President and CEO of InterMune, will present a corporate overview at the 5th Annual JMP Securities Research Conference in San Francisco on Thursday, March 9, 2006 at 1:15 p.m. Pacific time. To access the live audio webcast, log on to the investor relations page of InterMune’s website at www.intermune.com. The Company recommends logging on 15 minutes early in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Actimmune(R) (interferon gamma-1b), which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second- generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading “Risk Factors” in InterMune’s quarterly report on Form 10-Q filed with the SEC on November 7, 2005 (the “Form 10-Q”) and other periodic reports filed with the SEC.
InterMune, Inc.
CONTACT: investors, Judy Hayes of InterMune, Inc., +1-415-466-2242, orir@intermune.com, or media, Pam Lord of Atkins + Associates,+1-858-527-3494, or plord@irpr.com, for InterMune, Inc.
Web site: http://www.intermune.com/
